Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [11C]-(+)-PHNO
Sign Up to like & getrecommendations! Published in 2019 at "Psychopharmacology"
DOI: 10.1007/s00213-019-05387-w
Abstract: F17464, a dopamine D3 receptor antagonist with relatively high D3 selectivity (70 fold vs D2 in vitro), exhibits an antipsychotic profile in preclinical studies, and therapeutic efficacy was demonstrated in a randomized placebo-controlled clinical trial… read more here.
Keywords: receptor occupancy; study healthy; 11c phno; f17464 dopamine ... See more keywords
Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of clinical pharmacology"
DOI: 10.1007/s00228-020-03004-w
Abstract: PURPOSE Iberdomide is a cereblon E3 ligase modulator capable of redirecting the protein degradation machinery of the cell towards the elimination of target proteins potentially driving therapeutic effects. In vitro studies demonstrated that iberdomide predominantly… read more here.
Keywords: iberdomide; drug; study healthy; healthy subjects ... See more keywords
EDP‐297: A novel, farnesoid X receptor agonist—Results of a phase I study in healthy subjects
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Science"
DOI: 10.1111/cts.13453
Abstract: EDP‐297 is a farnesoid X receptor agonist under development for treating nonalcoholic steatohepatitis. The pharmacokinetic (PK), pharmacodynamic (PD), food effect, and safety were evaluated in a single ascending dose (SAD) and multiple ascending dose (MAD)… read more here.
Keywords: farnesoid receptor; edp 297; study healthy; phase study ... See more keywords